Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Common Equity: 2009-2025

Historic Common Equity for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $26.1 million.

  • Cumberland Pharmaceuticals' Common Equity rose 5.41% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 5.41%. This contributed to the annual value of $22.9 million for FY2024, which is 22.80% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Common Equity of $26.1 million as of Q3 2025, which was down 6.68% from $28.0 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Common Equity high stood at $48.0 million for Q2 2021, and its period low was $22.9 million during Q4 2024.
  • For the 3-year period, Cumberland Pharmaceuticals' Common Equity averaged around $29.4 million, with its median value being $28.0 million (2025).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 31.15% in 2024, then increased by 6.23% in 2025.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Common Equity stood at $42.8 million in 2021, then declined by 15.29% to $36.3 million in 2022, then declined by 18.37% to $29.6 million in 2023, then declined by 22.80% to $22.9 million in 2024, then climbed by 5.41% to $26.1 million in 2025.
  • Its Common Equity stands at $26.1 million for Q3 2025, versus $28.0 million for Q2 2025 and $28.7 million for Q1 2025.